cerrar
Tagged with Rare disease

Aurora Berra – General Manager, Sobi Spain and Portugal
Aurora Berra, general manager of Sobi Spain and Portugal, highlights her key priorities and the opportunities and challenges inherent in the…

The Technology Driving Rare Disease Pipelines
Rhenu Buller, an expert on disruptive technologies at business consultancy Frost & Sullivan's Asia Pacific office, outlines the technological…

Orphan Drug Accessibility & Social Medical Coverage in China
Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is…

Rethinking Clinical Trials in Rare Diseases
Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances,  access to rare…

Min-Young Kim – General Manager, Ipsen Korea
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology…

5 Key Trends in Orphan Drugs & Rare Diseases
Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space…

5 Rare Diseases You Should Know
The 28th February 2019, marks the twelfth international Rare Disease Day. On and around this day hundreds of patient organisations from countries and…

Rare Disease Company Acquisitions Continue Apace
Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma…

Rare Diseases in South Africa: Bridging the Gap for Inclusive…
Kelly du Plessis is CEO & Founder of Rare Diseases South Africa, a registered NPO born out of necessity when her oldest child was diagnosed with…

South Korea Gives the Green Light to Imports of Medical Cannabis
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will…

Top 10 Orphan Drugs in the USA
The Top 10 bestselling orphan drugs in the USA in 2017. Celgene's Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion,…

Top 10 Global Orphan Drug Companies Ranking 2017
The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here